Merck KGaA and Avillion inked a clinical co-development deal today for Merck’s anti IL-17 A/F Nanobody therapy for plaque psoriasis. The financial terms of the deal were not disclosed. The investigational treatment underwent Phase I development and the group plans to initiate Phase II trials this year. According to the terms of the agreement, Avillion […]
